← Back to MiMOUD
MiMOUD · Episode 04

Methadone Buprenorphine

How can a medication transition protect patient comfort, confidence, and continued engagement in care?

Audio ready · 1:41 · 10:53 · 24:10

Listen first

This is a calm, source-grounded clinician conversation. It centers the patient’s fear of becoming sick enough to give up, then walks through the conventional transfer pathway, the limits of a calendar-only waiting rule, precipitated withdrawal, and when a plan needs to pause or change.

⚡ Quick listen · 1:41

🎙️ Deep dive · 10:53

🧭 Source critique · 24:10

🎬 Video overview · 8:25

The critique is generated from the eight-source notebook and is published for listening review. Verify clinical claims against the source ledger; human addiction-medicine review remains required before clinical use.

Editorial position: traditional withdrawal-based transfer is the main teaching pathway here. Low-dose initiation with opioid continuation is labeled as an emerging, clinician-supervised option—not a generic home recipe or a universal recommendation.
Episode spine

Comfort is part of safety

  1. Why the patient wants to switch—and why buprenorphine is not automatically “better.”
  2. Why methadone’s long, variable persistence makes timing individualized.
  3. Traditional transfer: taper when appropriate, stop, assess objective moderate withdrawal, then start cautiously with monitoring.
  4. Low-dose initiation with opioid continuation: what it tries to solve, and what remains uncertain.
  5. What a credible support and contingency plan looks like.
  6. How to respond to precipitated withdrawal without blame or abandonment.